vision study update on benefit of lu-psma | david vanderweele, md | asco22 prostate cancer updates
Published 2 years ago • 50 plays • Length 0:23Download video MP4
Download video MP3
Similar videos
-
0:51
therap trial of 177lu-psma-617 review | david vanderweele, md | asco22 prostate cancer updates
-
11:07
phase 3 vision study of 177lupsma 617 for metastatic castration-resistant prostate cancer
-
6:45
177lu-psma-617 for prostate cancer: therap, vision, upfrontpsma and lutectomy
-
3:03
vision: tolerability of 177lu-psma-617 by treatment exposure in patients with mcrpc
-
5:37
177lu-psma-617 for the early treatment of prostate cancer
-
3:56
vision: 177lu-psma-617 in psma-positive mcrpc
-
6:43
does sugar feed prostate cancer? does fatty/adipose tissue attract cancer? | mark moyad, md, mph
-
40:03
psma & lutetium-177 in 2022 | eugene kwon, md | diy combat manual for beating prostate cancer part 4
-
6:47
patient's journey: experience with mcrpc and the lutetium (pluvicto) shortage
-
1:17
prince: 177lu-psma-617 and pembrolizumab in prostate cancer
-
4:48
vision: lu-177-psma-617 in mcrpc
-
14:05
lutetium 177 psma - problems with the vision trial
-
7:14
vision study
-
6:24
phase iii study of lutetium-177-psma-617 in patients with metastatic castration-resistant prosta...
-
8:31
recent updates in prostate cancer: stampede, vision & profound
-
10:28
anzup therap study (lu-177 psma-617 vs. cabazitaxel): overall survival after 3 years follow-up
-
1:10:05
psma scans & pluvicto (lutetium-177) in 2022 | geoffrey johnson, md, phd | pcri conference 2022
-
1:07
dr. penson on treatment selection in metastatic hormone-sensitive prostate cancer
-
5:58
need to know: experience with lutetium (pluvicto) for prostate cancer theranostics
-
1:54
steve’s experience of 177lutietum psma therapy - patient stories at genesiscare